Proactive Investors - Run By Investors For Investors

Eden Research chairman to highlight key milestones and good commercialisation progress at AGM

Lykele van der Broek will tell shareholders: "Eden is well-placed to sustainably and effectively meet many of the current and future needs of growers”
Tomatoes
He added: “Eden's products align perfectly with the course set for the industry by changing public policy and increasingly challenging regulations"

Eden Research PLC’s (LON:EDEN) chairman, Lykele van der Broek will highlight the key milestones and good progress made with the commercialisation and regulatory clearance of its products at the biopesticides firm’s annual general meeting, to be held on Tuesday, as the group moves to benefit from changes to the agchem industry.

In a statement to be delivered at the meeting, van der Broek said: “It is clear that the world of agchem, whilst inherently conservative, is swiftly undergoing major disruption due to external drivers such as regulatory issues, resistance problems with conventional pesticides, and the ever-increasing cost of the registration of new products.”

READ: Eden Research partner make first sales in Italy of breakthrough bio-pesticide

“In this environment of turmoil and disruption caused by the removal of important conventional pesticides from global markets at a rate that is troubling for farmers, Eden is well-placed to sustainably and effectively meet many of the current and future needs of growers.”

He added: “Eden's products align perfectly with the course set for the industry by changing public policy and increasingly challenging regulations, and we aim to ensure that the Company, our shareholders, growers and our commercial partners benefit from the success that this alignment will bring."

Already this year, Eden's commercial partner, Eastman Chemical has received authorisation for Eden's nematicide formulation, marketed as Cedroz, from the Regulatory Affairs Directorate in Malta.

Additionally, an emergency authorisation has recently  been granted in Italy by the Italian Ministry of Agriculture which gives an indication as to the need for this type of product in the market and has resulted in the first commercial sales of Cedroz.

At the end of last calendar year, Eden's commercial partner, Sipcam Oxon SpA, paid €0.9mln for the exclusive right to sell Mevalone in ten additional countries, including the US, China and Brazil.

During 2018, sales of Mevalone more than doubled to £1.6mln helping Eden to achieve overall revenue of £2.8mln.

Eden’s chairman said: “This growth was generated by essentially the same commercial ‘footprint’ that was in place in 2017, which is a good like-for-like comparison reflecting a growing market share and strong product adoption of our first product.”

View full EDEN profile View Profile

Eden Research Timeline

Related Articles

Grape bunches
April 03 2019
Eden Research's first product Mevalone, a grape fungicide which is used to target the botrytis disease, is currently being sold throughout the southern EU zone and Kenya
Graphene
February 18 2019
The firm specialises in using nanomaterials, including graphene, to improve or enhance the properties of products such as plastics or ceramics
Itaconix
January 23 2019
Itaconix’s technology has been well-received as highlighted by the recent deals signed with Nouryon and New Wave.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use